To realize the goal of eliminating the viral hepatitis threat by 2030 proposed by WHO, and promote the department cooperation of Chinese medical institutions to conduct the hospital screening of hepatitis C, under the guidance of honorary chairman Zhuang Hui and led by chairman Wei Lai, China Liver Health invited famous experts in the field of liver disease, inspection and infection control to compile the Management Process of Hepatitis C Hospital Screening of China.
Group
photo of attendants The
first expert seminar was held on February
27,2021 in Beijing. More than 20 experts attended on site and on line. Prof.
Wei Lai, chairman of China Liver Health, and prof.Xu Xiaoyuan, chairman of
Chinese Society of Hepatology, Chinese Medical Association, presided over the
meeting. Gilead Sciences and Roche
Diagnostics provided public welfare support.
Prof. Wei Lai, chairman of
China Liver Health
Prof. Xu Xiaoyuan, chairman of
Chinese Society of Hepatology, Chinese Medical Association Prof. Duan Zhongping, former
chairman of Chinese Society of Hepatology, Chinese Medical Association,was
invited to deliver the opening speech. Prof. Nan Yuemin, chairman of Chinese
Society of Hepatology, Chinese Medical Association,interpreted the treatment of
hepatitis C in China according to the guideline of prevention and treatment for chronic
hepatitis C(2019edition). Wu chao, deputy director of Nanjing Drum Tower
Hospital, introduced the establishment of new clinical pathway of screening
diagnosis and treatment of Hepatitis C in 3A grade hospitals of Jiangsu
Province.
Prof.Duan Zhongping, chairman
of Chinese Society of Hepatology, Chinese Medical Association
Prof. Nan Yuemin, chairman of
Chinese Society of Hepatology, Chinese Medical Association
Prof. Nan Yuemin, chairman of
Chinese Society of Hepatology, Chinese Medical Association Prof. Feng Bo and prof. Gao
Yan from Peking University People’s Hospital reported the compilation ideas and
progress of the Management Process of Hepatitis C Hospital Screening. Prof. Pan
Shiyang(from Jiangsu Province Hospital, deputy chairman of Chinese Society of
Laboratory Medicine, Chinese Medical Association ) gave the compilation advice
systematically based on the perspective of inspection.
Prof.
Feng Bo from
Peking University People’s Hospital
Prof. Gao Yan from Peking
University People’s Hospital
Prof. Pan Shiyang, deputy
chairman of Chinese Society of Laboratory Medicine, Chinese Medical Association Hepatitis C is one of the most important causes of end-stage liver diseases
such as cirrhosis and liver cancer. The hepatitis C infected people in China
has reached a number of 10 million. General screening is not possible due to
the 0.43% anti-HCV positive rate in the general population. According to
certain domestic and foreign studies，hepatitis C screening with cross-department cooperation inside the hospital
revealed good results with low cost and convenient referral treatment. With the
important experiences explored by some hospitals, experts could summarize to
comply the guide files with speciality, operability and generalizability.
Therefore，under the guidance of
honorary chairman Zhuang Hui and led by chairman Wei Lai, China Liver Health invited
famous experts with distinguished attainments in the field of liver disease,
inspection and infection control to promote the work in form of editorial
committee. Prof. Feng Bo from Peking University
People’s Hospital, prof.Guan Xiuru from First Affiliated Hospital of Harbin
Medical University and prof.Gao Yan from Peking University
People’s Hospital were invited to compile the first draft of the Management Process of Hepatitis C Hospital Screening of China.
At the seminar, experts discussed and commended the draft, and gave
the optimize suggestions. Prof.Nan Yuemin from The Third Hospital of Hebei Medical University, prof.Hu Bijie from Zhongshan Hospital, Fudan University, prof. Liu Yunxi from Chinese PLA General Hospital, prof.Hou Tieying from Guangdong Province People’s Hospital,prof.Yu Yunsong from Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, prof. Zhang Xinxin from Ruijin Hospital, Shanghai Jiaotong University School of Medicine,prof.Ou Qishui from The First Affiliated Hospital of Fujian Medical University, prof. Zhang Jingping from the First Affiliated Hospital of China Medical University,profe.Li Boan from The Fifth Medical Center of PLA General Hospital, profe. Zheng Lei from Nanfang Hospital, Southern Medical University, prof.Li Jun from Jiangsu Province Hospital, prof. Wang Lei from The Second Hospital of Shandong University,prof.Li Liuyi from Peking University First Hospital, and deputy director Gong Yanwen of The Second Hospital of Shandong University(entrusted by president Wang Chuanxin to attend the meeting) delivered speeches one after another.
Prof.Wei Lai gave thanks to the experts for their
valuable opinions，which he said will be taken as important references
for the compiling experts in revising the manuscript.
After the brief summary of prof.Duan Zhongping, Wu
Chao, Feng Bo and Gao Yan, prof.Xu Xiaoyuan delivered a summary speech. He said
that the focus of eliminating hepatitis C in China was converting from clinical
treatment to patient search, we should rely on government guidance, learn from
the experience of COVID-19 prevention, control and testing system, adopt new
technologies and new patterns to activate different departments of the hospital
to work together, and make efforts to eliminate the hepatitis C threat by 2030.
Shen Yingsheng, deputy director
of China Liver Health Entrusted
by director Li Mingyang, deputy director Shen Yingsheng introduced China Liver
Health and China Hepatitis C Elimination Alliance Public Welfare Project to the
experts at the meeting. Directors of public welfare partners of Gilead Sciences and Roche Diagnostics attended the
seminar.
At the meeting site |
关注官方微信 
